Natco Pharma Share Price in Focus as Board Approves Rights Issue for ₹1,279 Crore

Natco Pharma Limited's board has approved a significant capital raising initiative through a rights issue, aiming to generate up to ₹1,279.36 crore.  

The decision was made during a board meeting held on September 25, 2026, aligning with SEBI regulations, as per the exchange filings. 

Details of the Rights Issue 

The rights issue involves the issuance of 1,70,58,082 new equity shares, each with a face value of ₹2. The shares are priced at ₹750, including an equity premium of ₹748 per share.  

Investors eligible for this offer must hold shares by the record date, set for October 1, 2026. 

The subscription window for the rights issue will open on October 12, 2026, and close on October 22, 2026. During this period, trading rights can be renounced from October 12 to October 16, 2026. 

Impact on Share Capital 

Before the rights issue, Natco Pharma's equity base consisted of 17,91,09,870 shares. If fully subscribed, the new issue will increase the total share count to 19,61,67,952 shares. The International Securities Identification Number for these rights entitlements is INE987B20018. 

Entitlement Ratio and Abeyance 

Eligible shareholders will receive 2 new shares for every 21 shares held. Fractional entitlements below the 21-share threshold will be discarded, with preferential status given for unallocated shares. Entitlements linked to disputed or legally challenged holdings will be held in abeyance until resolved. 

Read More: Max Estates Share Price Surges Over 5%: To Enter a Prosposed JDA for a Land Parcel in Ghaziabad! 

NATCO Pharma Share Price Performance 

As of September 25, 2026, at 11:54 AM, NATCO Pharma share price on NSE was trading at ₹844.55, up by 0.30% from the previous closing price. 

Conclusion 

Natco Pharma's board-approved rights issue aims to raise ₹1,279.36 crore through the issuance of 1,70,58,082 shares at ₹750 each. The record date is set for October 1, 2026, with the subscription window from October 12 to October 22, 2026. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.